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Abstract
The characterisation of monoclonal antibodies (MAbs) and their epitopes is important prior to their application as molecular
probes. In this study, Western blotting using IgG1 Fc and pFc? fragments was employed to screen seven MAbs before pepscan
analysis to determine their reactivity to potentially linear epitopes. MAbs PNF69C, PNF110A, X1A11 and MAbs WC2, G7C,
JD312, 1A1 detected epitopes within the CH3 and CH2 domains, respectively. However, only four MAbs showed pepscan profiles
that highlighted likely target residues. In particular, MAbs PNF69C and PNF110A that have previously been characterised with
pan-IgG and anti-G3m(u) specificity, detected the peptide motif 338-KAKGQPR-344 which was located within the N-terminal
region of the CH3 domain. Furthermore the majority of residues were present in all four IgG subclasses. Consequently the peptide
identified was consistent with the pan-IgG nature of these antibodies. By using PCImdad, a molecular display programme, this
sequence was visualised as surface accessible, located in the CH2/CH3 inter-domain region and proximal to the residue arginine435. It
is speculated that this residue may be important for phenotypic expression of G3m(u) and specificity of these reagents. Pepscan
analysis of MAbs G7C and JD312 (both pan-IgG) highlighted the core peptide sequence 290-KPREE-294, which was present in the
CH2 domain and was common to all four IgG subclasses. PCImdad also showed this region to be highly accessible and was
consistent with previous bioinformatic and autoimmune analysis of IgG. Overall these MAbs may serve as useful anti-IgG or anti-
G3m(u) reagents and probes of immunoglobulin structure.
# 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Assay restriction is a common feature and problem of
monoclonal antibodies (MAbs). In essence, MAbs may
perform well in some assay systems but may be poor or
ineffective in others [1,2]. In addition, the specificity of a
given reagent can also be determined by the assay
system employed [3]. This phenomenon relates to the
nature and display of the antigenic determinant, or
epitope, and whether it is modified (or denatured) as a
result of procedures used within an assay technique [3].
Consequently the characteristics of an antibody’s target
epitope in terms of location, composition of amino acids
and accessibility are highly significant together with
issues of antibody specificity and reactivity in the
development of secure assay systems [4]. To this end,
pepscan methodologies which employ a series of over-
lapping synthetic peptides of a given protein have
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provided an effective means of identifying key residues
for antibody recognition and binding [5]. Overall,
pepscan analysis employing peptides immobilised on
polyethylene pins has been satisfactorily used to identify
MAb reactivity to continuous epitopes [6]. However, a
disadvantage of this particular methodology has been
the uncertainty of peptide regeneration and thus peps-
can using biotinylated peptides (attached to streptavidin
coated plates) has also been employed [7]. In general,
pepscan methodologies provide greater resolution of
target residues compared with gross epitope mapping
techniques such as enzyme degradation and cyanogen
bromide cleavage, which allow the localisation of anti-
body reactivity to particular fragments [1].
Monoclonal reagents are widely used within the
biomedical sciences and readily enable the standardisa-
tion of both reagent and assay technique because they
are specific and can be generated in unlimited quantities
in vitro [8]. Earlier studies [9,10] have demonstrated two
MAbs (PNF69C and PNF110A) with assay restriction
profiles. Of interest is that both MAbs exhibit pan-IgG
and anti-G3m(u) specificity in indirect ELISA/haemag-
glutination (HA) and capture ELISA/haemagglutina-
tion-inhibition (HAI), respectively. Both MAbs were
derived from the same fusion but originated from
different hybridoma cell lines. Both reagents may prove
useful pan-IgG or anti-allotypic antibodies e.g. for
clinical/forensic serology [11], although the target epi-
tope(s) recognised by these antibodies remains unclear.
A previous report [12] has successfully employed
biotinylated 15 mer overlapping peptides of IgG Fc to
identify the target epitope of an in-house and commer-
cially available pan-IgG monoclonal reagent, MAb
A57H. This antibody recognised a peptide sequence
383-SNGQPENN-390 (Eu numbering, single amino
acid code) that was found on all four IgG subclasses
and straddled the fy1 strand and the b3 loop of the CH3
domain [13]. As an extension to this work, we have used
these peptides to map potential epitopes of MAbs
PNF69C and PNF110A and five other anti-IgG Fc
MAbs (X1A11, WC2, G7C, JD312, 1A1) previously
characterised with regard to subclass specificity.
Furthermore by employing a software programme
‘PCImdad’ we have been able to demonstrate the
surface topography and accessibility of potential IgG
target epitope’s identified through pepscan analysis.
2. Materials and methods
2.1. Monoclonal antibodies
The generation and specificity of MAbs used in this
study (PNF69C, PNF110A, X1A11, WC2, G7C, JD312
and 1A1) with regard to IgG subclass, allotypic (Gm)
markers, deleted paraproteins and IgG fragments have
previously been reported [9,14/16]. These reagents have
been characterised using a combination of techniques
including haemagglutination (HA), haemagglutination-
inhibition (HAI) and enzyme linked immunosorbent
assay (ELISA). Five MAbs (TM15, ZB8, GOM1, ZG4
and RJ4) with reactivity to regions other than IgG1 Fc
were used as controls and represented the predominant
mouse isotype under investigation. Ascites (1 mg/ml)
was used as a source of monoclonal reagent for all
investigations.
2.2. Western blot analysis
Western blotting of MAbs was performed using
standard procedures [1] on previously characterised
paraproteins: PER (IgG1 Fc), pFc? PER (pepsin diges-
tion product of Fc PER) [2,12/14] to ascertain reactivity
to linear antigenic determinants. In brief, equal amounts
(5 mg) of immunoglobulin preparations either containing
2-mercaptoethanol (denatured) or without reducing
agent, were separated on SDS-12% polyacrylamide
Laemmli gels. Proteins were then transferred onto
nitrocellulose membrane (Hybond-C: Amersham Phar-
macia Biotech Ltd., Little Chalfont, UK) and mem-
branes blocked using 5% milk powder (Marvel) in PBS/
Tween (0.1%). MAbs were used at a concentration of 30
mg/ml diluted in PBS/Tween (0.1%). An anti-mouse
horseradish peroxidase-conjugated secondary antibody
(DAKO, UK) was used for the detection of transferred
bands in conjunction with the enhanced chemilumines-
cence system (ECL, Amersham-Pharmacia Biotech UK
Ltd.). The standard immunodetection protocol as de-
tailed in the ECL handbook was used and the exposure
time was 15 s.
2.3. Synthetic peptides
Ninety-four 15 mer peptides were provided by Mi-
motopes Pty Ltd., based on the human IgG1 Fc region,
sequence NIE [17] and biotinylated at the N-terminus.
Peptides were initially reconstituted in 200 ml DMSO
and subsequently diluted in phosphate buffer diluent
(see below) to give a final concentration of 1 nmol/ml.
Peptides spanned most of the CH2 and CH3 domains:
commencing 238-PSVFLFPPKPKDTLM-252 and ter-
minating 424-FSCSVMHEALHNHYT-438. All resi-
dues were related to the Eu numbering index [17] and
the offset for overlapping peptides was two e.g.
SRDELTKNQVSLTCL (354/368), DELTKNQVSLT-
CLVK (356/370). Sequences NIE and EU are virtually
identical [17] although NIE possesses an additional
residue: aspartic acid389. In addition, EU and NIE
exhibit amino acid replacements of glutamic acid294
with glutamine294, respectively.
P.N. Nelson et al. / Immunology Letters 88 (2003) 77/8378
2.4. Pepscan assay
Flat bottomed plastic microtitre plates (Nunc: Life
Technologies, Paisley, UK) were coated with 100 ml of a
5 mg/ml solution of streptavidin (Sigma, Poole, UK) and
left uncovered at 37 8C for at least 16 h until they had
evaporated to dryness. The plates were washed using
tapwater and each well blocked with 200 ml of a 2%
solution of BSA in 0.1 M PBS pH 7.2. Plates were
incubated for 1 h at room temperature, with agitation,
and washed (x4) in PBS/Tween 20 (0.1% v/v). Peptides
were prepared in diluent: PBS containing Tween 20
(0.1% v/v) and sodium azide (0.1% w/v), and 100 ml
added to each well (ca. 30 pmol of biotinylated peptide
per well). Plates were incubated for 1 h at room
temperature, with agitation, and then washed (x4) in
PBS/Tween. MAb ascites were diluted 1/1000 in diluent
and added to wells (100 ml). Plates were incubated for 1
h at room temperature with agitation and then washed
(x4). Finally peroxidase-conjugated goat anti-mouse
immunoglobulin (DAKO, Cambridge, U.K.) was opti-
mally diluted (1/1000) in 0.01 M PBS pH 7.2 containing
1% v/v sheep serum, 0.1% v/v Tween 20, 0.1% w/v
sodium caseinate and applied to wells (100 ml/well):
plates were incubated for 1 h at room temperature with
agitation. Following washing, 100 ml of ABTS (Sigma,
Poole, UK) substrate (dissolved in 0.1 M di-sodium
hydrogen orthophosphate, 0.08 M citric acid) contain-
ing 0.01% w/v H2O2 was added to each well. The colour
reaction was allowed to proceed for 30 min and the OD
read at 405 nm using a Titertek Multiscan MC micro-
plate reader. OD values were provided as 0/2000
nominal OD Units (equivalent to the generally accepted
format 0.0/2.0 OD Units) [1/3]. The OD values
obtained from control MAbs were used to determine a
mean value for each peptide that was subtracted from all
other Pepscan profiles (for controls: range, 94/1071 OD
Units; mean, 230 OD Units, maximum OD [peptide 62,
360-KNQVSLTCLVKGFYP-374, followed by peptide
61, 358-LTKNQVSLTCLVKGF-372]).
2.5. PCImdad display
A PC interactive molecular display and design
programme (PCImdad) [18] was used to display poten-
tial amino acids on the Fc region of IgG derived from
Pepscan data. Key residues were highlighted and
displayed, employing space-filling and carbon backbone
modes, on an IgG Fc molecule [19].
3. Results
3.1. Western blotting
To ascertain the reactivity to potential linear epitopes
within IgG Fc, seven MAbs (PNF69C, PNF110A,
X1A11, WC2, G7C, JD312, 1A1) were evaluated by
Western blotting. In this system, both reduced and non-
reduced Fc and pFc? fragments were used and their
electrophoretic transfer to nitrocellulose validated by
previously characterised antibodies. The data (Table 1)
highlighted that MAbs PNF69C and PNF110A detected
both reduced and non-reduced pFc? (PER). MAbs
X1A11 and 1A1 were reactive with Fc and pFc?
fragments whilst MAbs WC2, G7C and JD312 were
reactive with Fc(PER), but not pFc? (PER).
3.2. Pepscan profiling
Out of seven antibodies tested, only four MAbs
(PNF69C, PNF110A, G7C and JD312) generated
Pepscan profiles. MAbs X1A11, WC2 and 1A11 showed
similar reactivity to peptides as control antibodies. The
Pepscan profile for MAb PNF69C (Fig. 1a) highlighted
antibody activity for peptides 47/51 with OD’s ranging
from 1500 to 2000 OD units. Identical peptides were
detected by MAb PNF110A (not shown) that on
alignment suggested a core peptide sequence: 338-
KAKGQPR-344. Both antibodies exhibited reactivity
for peptides 61 (358-LTKNQVSLTCLVKGF-372) and
62 (360-KNQVSLTCLVKGFYP-374) that was also
noted for all control MAbs tested. MAb G7C identified
peptides 23/26 (Fig. 2a) with antibody activity ranging
from 1500 to 2000 OD units. Marginally higher activity
(2000/2500 OD units) was also shown by MAb JD312
and included peptides 22/27. Alignment of peptides for
MAbs G7C and JD312 highlighted the core sequence:
290-KPREE-294.
Table 1
Reactivity of MAbs in Western blotting using IgG1 Fc and pFc?
fragments
Mab Fc(PER) pFc? (PER)
Non-red. Red. Non-red. Red.
PNF69C / / / /w
PNF110A / / / /
X1A11 / / / /
WC2 / NT / NT
G7C / / / /
JD312 / / / /
1A1 / NT / NT
Controls
A57H / / / /
A55 / / / /
MAbs were evaluated for reactivity in Western blotting against non-
reduced (non-red.) and reduced (red.) paraproteins Fc(PER) (MW 50
KDa) [9,15] and the pepsin derived fragment pFc? (PER) (MWt 25
KDa) [9,15]. / (positive), / (negative), NT (not tested), w (weak
band). Control MAbs A55 and A57H detected CH2 and CH3 domains,
respectively.
P.N. Nelson et al. / Immunology Letters 88 (2003) 77/83 79
3.3. PCImdad display
The location and surface topography of likely target
epitopes was visualised on an IgG molecule using the
space-filling mode. The core sequence 338-KAKGQPR-
344 (Fig. 1b) was present on an exposed peptide segment
(or loop) that bridged the fy3 face and the fx1 face of the
CH2 and CH3 domains, respectively. Conversely the
peptide sequence 290-KPREE-294 was located on the
fx3 face of the CH2 domain which was exposed and
solvent accessible (Fig. 2b) and thus capable of interac-
tion with antibody.
4. Discussion
Epitope mapping using pepscan provides a useful
adjunct to the characterisation of MAbs [4] and has
been used in identifying epitopes on macromolecules
including allergens and components of viruses [20,21].
However, an important caveat of pepscan is that the
technique is biased towards antibodies recognising
linear, as opposed to conformational epitopes. Petrakou
et al., [22] showed that only half of the MAbs
investigated using overlapping peptides of MUC1 mucin
yielded pepscan profiles. To circumvent this problem,
we initially tested our panel of MAbs in Western
blotting since the detergent sodium dodecyl sulphate
effectively linearises proteins for gel separation prior to
their transfer to nitrocellulose membrane [1]. In our
study all seven MAbs exhibited reactivity in Western
blotting: MAbs PNF69C, PNF110A, X1A11, 1A1 to
pFc?(PER) and MAbs WC2, G7C, JD312 to Fc(PER).
Since pepsin cleaves C-terminal to glutamic acid333 to
yield a pFc? fragment [13], it may be inferred that MAbs
WC2, G7C and JD312 bound to epitopes within the
CH2 domain of Fc(PER). Whilst it has been recognised
that some renaturation of proteins may occur following
SDS leaching i.e. during electrophoretic transfer [23], it
was likely that these antibodies bound to potentially
linear Fc epitopes. Overall preliminary evaluation of
antibodies in Western blotting confirmed previous CH2/
CH3 localisation studies of anti-Fc MAbs [9,15,16] but
was only partially successful since MAbs X1A11, WC2
and 1A1 did not yield pepscan profiles. In explanation,
it was plausible that these antibodies recognised quasi-
linear epitopes that were perhaps conformationally
constrained by amino acids upstream/downstream of
the target site. Furthermore, the weaker reactivity of
MAb PNF69C for its epitope on reduced pFc? may also
suggest some conformational constraints. Clearly the
use of small isolated peptides attached to microtiter
Fig. 1. (a) Pepscan anlaysis of MAb PNF69C. The profile for MAb PNF110A was similar and specific details are presented in text. (b) PCImdad of
peptide sequence 338-KAKGQPR-344 plus the position (arrowed) of arginine435.
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plate wells may have compromised antibody/epitope
interactions and it will be of interest to further evaluate
the epitopes of MAbs X1A11, WC2 and 1A1 using site-
directed mutagenesis [24] and phage display [25].
For MAbs PNF69C and PNF110A pepscan analysis
highlighted the core peptide sequence 338-KAKGQPR-
344 which was located at a position that included CH2/
CH3 interdomain residues and the N-terminal region of
the CH3 domain. Furthermore this motif was present in
all four IgG subclass proteins, although alanine339 was
substituted for threonine339 in IgG2 and IgG3 allotypic
variants (Table 2). A previous study [9] suggests that the
pan-IgG reactivity of both MAbs was independent of
this amino acid substitution. Thus pepscan of MAbs
PNF69C and PNF110A highlights a common IgG
subclass epitope that explains the pan-IgG nature of
these reagents. In using PCImdad the peptide was
characterised as highly accessible and, therefore, likely
to be antigenic. Interestingly epitope mapping of poly-
clonal and monoclonal rheumatoid factors [26/28]
highlights three CH3 domain epitopes (343-PRE-
PQVY-349, 346-PQVYTLP-352, 350-TLPPSRE-356)
that either overlap or are immediately adjacent to the
peptide motif 338-KAKGQPR-344. Taken together,
these studies reveal a highly antigenic region targeted
by autoimmune antibodies [28] and MAbs developed in
mice [9]. Evidently from previous studies using intact
IgG [9,15,16] the glycan moiety does not appear to
hinder the accessibility of MAbs PNF69C and
PNF110A for their target epitopes.
The location of the G3m(u) allotypic marker has
previously been suggested to reside within the CH2
domain of IgG3 and its expression linked to the
presence of threonine339 (CH2 domain) and possibly
arginine435 in the CH3 domain [29,30]. However, current
sequencing information [17] does not support a role for
threonine339 since Table 2 reveals that G3m(u) para-
proteins WI and OM contain threonine339 and ala-
nine339, respectively, whilst paraprotein JIR G3m(st)
possesses threonine339. This observation is also con-
firmed by Dard et al. [31] who investigated IgG3
allotypes in human populations other that G3m(u). In
our studies it was also apparent that alanine339 was
present within the peptide sequence 338-KAKGQPR-
344. Overall these observations suggest that the presence
alanine/threonine339 may be less significant in the
phenotypic expression of G3m(u). Consequently this
allotypic marker may be conformationally dependent
and necessitate one or more additional residues on
IgG3. Intriguingly Table 2 shows that IgG3 variants
expressing G3m(gu) and G3m(bu) possess arginine435
whilst IgG1, IgG2, IgG4 and G3m(st) paraproteins
Fig. 2. (a) Pepscan anlaysis of MAb G7C. The profile for MAb JD312 was similar and specific details are presented in text. (b) PCImdad of peptide
sequence 290-KPREE-294.
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possess histidine435. In using PCImdad, we show that
residue 435 is surface accessible and spatially orientated
adjacent to the peptide sequence 338-KAKGQPR-344.
Consequently we speculate that the proximity of argi-
nine435 in conjunction with the peptide motif may play a
role in the conformation and phenotypic expression of
G3m(u). It is, therefore, conceivable that the manner of
epitope display afforded by different assay systems
could influence the ‘dual’ reactivity i.e. anti-G3m(u)/
pan-IgG of MAbs PNF69C and PNF110A observed in
previous studies [9,14]. In the latter, G3m(u) specificity
was shown when IgG was captured in ELISA or coated
onto red blood cells whereas pan-IgG reactivity was
noted with IgG coated directly onto microtitre plates. In
this case, hydrophobic interactions between immuno-
globulin and a plastic surface could bias the reactivity
towards a common IgG epitope as opposed to a
potential conformation (G3m(u)) epitope.
Epitope mapping of MAbs G7C and JD312 identified
the core peptide sequence 290-KPREE-294 that was
present in all four IgG subclasses (Table 2) and was
consistent with the pan-IgG reactivity exhibited by these
antibodies in previous studies [15,16]. The latter also
serve to demonstrate that the binding of MAbs G7C and
JD312 to IgG is not rendered inaccessible by oligosac-
charide moieties linked via asparagine297 [32] or influ-
enced by leucine291. PCImdad also highlighted a surface
topography for this motif that was highly exposed,
solvent accessible and on a loop region (i.e. connecting
two ß-strands). These observations were consistent with
bioinformatic tools [33] which have been used to predict
regions of antigenicity on IgG1 Fc [34]: analysis shows
the sequence 290-KPREQQYN-297 as extremely hydro-
philic and thus a likely antigenic site within the CH2
domain. Intriguingly pepscan analysis of rheumatoid
factors [26/28] likewise highlight an epitope (274-
KFNWYVD-280) adjacent to the peptide sequence
290-KPREE-294 suggesting a key CH2 antigenic region.
Pepscan of all seven MAbs showed reactivity to
peptide 62 (360-KNQVSLTCLVKGFYP-374) and to a
lesser extent peptide 61 (358-AAQVSLTCLVKGF-372).
Since this phenomenon was observed for all control
antibodies, it was unlikely that these peptides repre-
sented a major epitope for MAbs PNF69C, PNF110A,
G7C and JD312. It was possible that some reactivity
could be attributed to non-specific interactions of
peptide, MAb and secondary antibody. In terms of
location, peptide 62 was situated on the b1 loop and
proximal region of the fx2 face of the CH3 domain [13].
Hence this peptide was remote to the CH2/CH3 domain
interface and thus unlikely to contribute to epitope(s)
recognised by MAbs PNF69C and PNF110A. Minor
variations in pepscan profiles were also observed for
MAb pairs PNF69C, PNF110A and G7C, JD312 that
could reflect subtle differences in the spatial orientation
of a MAb for a given epitope. Similar variations in
reactivity have been reported in other studies [15,16].
Interestingly preliminary data from BIAcore analysis
[35] using purified IgG paraprotein immobilised with a
goat anti-mouse antibody, highlights differing affinity
constants [PNF69C (4/107 per M), PNF110A (7.14/
107 per M), G7C (2.70/108 per M), JD312 (2.86/108
per M), TM15 (2/108 per M)] that might reflect subtle
variations in Mab/epitope interactions.
The present study has shown the combination of
pepscan and surface topography visualisation as a
means of localising and characterising epitopes of a
panel of anti-IgG Fc monoclonal reagents. It is specu-
Table 2
Location of motifs identified through pepscan within IgG subclasses and Gm allotypic variants
Eu index IgG1 IgG2 IgG3 IgG4
Eu(f) Cl(za) Cl(n) WI(bu) OM(gu) aJIR(st) Cln G4m(a)
290 Lys Lys Lys Lys Lys Lys Lys Motif: K
MAb: 291 Pro Pro Pro Pro Leu Pro Pro P
G7C 292 Arg Arg Arg Arg Arg Arg Arg R
JD312 293 Glu Glu Glu Glu Glu Glu Glu E
294 Gln Glu Glu Glu Glu Gln Glu E
338 Lys Lys Lys Lys Lys Lys Lys Motif: K
Mab: 339 Ala Ala Thr Thr Ala Thr Ala A
PNF69C 340 Lys Lys Lys Lys Lys Lys Lys K
PNF110A 341 Gly Gly Gly Gly Gly Gly Gly G
342 Gln Gln Gln Gln Gln Gln Gln Q
343 Pro Pro Pro Pro Pro Pro Pro P
344 Arg Arg Arg Arg Arg Arg Arg R
435 His His His Arg Arg His His
Key allotypic residues shown in italic: Thr339 associated with G3m(u) [26,27] but also present in JIR G3m(st).
a Note that paraprotein GOE G3m(st) possesses Ala339 together with paraproteins OM G3m(gu). Leu291 is associated with G3m(g) [10]. Core
pepscan motifs shown in bold (single letter amino acid code: K, lysine; A, alanine; G, glycine; Q, glutamine; P, proline; R, arginine; E, glutamic acid).
Arg435, present in paraproteins expressing G3m(u) is underlined.
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lated that the anti-G3m(u) specificity of MAbs PNF69C
and PNF110A may be influenced by the presence of
arginine435 in proximity to the peptide motif expressed
in all four IgG subclasses. Overall the MAbs investi-
gated in this study may prove useful probes of antigenic
structure e.g. for evaluating recombinant antibodies, or
reagents for diagnostic/forensic purposes. In addition,
they may serve in functional assays to inhibit the
binding of neonatal FcRn (MAbs G7C, JD312) and
Streptococcal protein G (MAbs PNF69C and
PNF110A) [30].
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